Skip to main content

Table 2 Association between aspirin use after diagnosis and CRC-specific and overall survival in patients with colorectal cancer

From: Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study

 

Mortality

Patients

Person years

Unadjusted HR

(95% CI)

P value

Adjusteda HR

(95% CI)

P value

CRC-specific survival

 Aspirin non-user

729

5881

15,957

1.00 (ref. cat.)

 

1.00 (ref. cat.)

 

 Aspirin user

335

2510

6178

1.22 (1.07, 1.39)

0.003

1.17 (1.00, 1.36)

0.06

 1 to 365 DDDs vs. non-user

160

725

2549

1.34 (1.12, 1.59)

0.001

1.23 (1.02, 1.50)

0.03

  ≥ 365 DDDs vs. non-user

175

1785

3629

1.12 (0.95, 1.33)

0.18

1.10 (0.90, 1.33)

0.36

Overall survival

 Aspirin non-user

1035

5881

15,957

1.00 (ref. cat.)

 

1.00 (ref. cat.)

 

 Aspirin user

600

2510

6178

1.51 (1.37, 1.67)

< 0.001

1.21 (1.07, 1.37)

0.002

 1 to 365 DDDs vs. non-user

263

725

2549

1.59 (1.39, 1.83)

< 0.001

1.26 (1.08, 1.46)

0.004

  ≥ 365 DDDs vs. non-user

337

1785

3629

1.45 (1.28, 1.65)

< 0.001

1.18 (1.02, 1.37)

0.03

  1. Abbreviations: CI confidence interval, CRC colorectal cancer, DDD daily defined dose, HR hazard ratio
  2. aMultivariable model contains age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and statin use (as a time-varying covariate)